Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches
- 29 September 2021
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (1) , 159-174
Abstract
The most common adverse event associated with chimeric antigen receptor T-cell therapy is cytokine release syndrome, which is characterized by fever, hypoxia, and hypotension in varying degrees of severity. In severe cases, cytokine release syndrome can result in life-threatening symptoms such as multi-organ failure. The widely accepted first-line therapy for cytokine release syndrome management is tocilizumab with or without corticosteroids, but there is very limited guidance on the proper management of patients unresponsive to this regimen. There are emerging strategies that target cytokine release syndrome through novel mechanisms, showing promise in treating or preventing severe cytokine release syndrome. Although further clinical investigation is necessary to assess the applicability of the emerging approaches, these exploratory therapies may shape the future landscape of chimeric antigen receptor T-cell induced cytokine release syndrome management. This review article provides a comprehensive overview of the current and emerging therapies for the management of chimeric antigen receptor T-cell induced cytokine release syndrome, especially cases that are refractory to tocilizumab and steroids.Keywords
This publication has 64 references indexed in Scilit:
- Future directions in chimeric antigen receptor T cell therapyCurrent Opinion in Pediatrics, 2017
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaScience Translational Medicine, 2015
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6International Journal of Biological Sciences, 2012
- Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2011
- Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophilsBlood, 2007
- Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cellsJournal of Experimental Medicine, 2005
- Prednisone increases apoptosis inin vitroactivated human peripheral blood T lymphocytesClinical and Experimental Immunology, 1996